Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin Plans $850 Million Notes for Amicus Deal; 2025 Revenue About $3.2 Billion

Neutral Impact 4 of 5 m&a Written later

BioMarin estimated unaudited 2025 total revenues of about $3.2 billion and cash, equivalents and investments of about $2.1 billion as of December 31, 2025, ahead of full results due in February 2026. It also announced plans for an $850 million senior unsecured notes offering and a new $2 billion senior secured term loan B, which it says will help fund its pending acquisition of Amicus Therapeutics, adding substantial new debt for shareholders to weigh.

Key points

  • Preliminary 2025 total revenues of about $3.2 billion, including about $920 million from VOXZOGO sales (unaudited)
  • Cash, cash equivalents and investments of about $2.1 billion as of December 31, 2025 (unaudited)
  • Planned $850 million senior unsecured notes due 2034 in a private placement; gross proceeds to be held in escrow pending the Amicus acquisition
  • Amicus holders to receive $14.50 per share in cash; aggregate transaction value of about $5,235.0 million; notes must be redeemed if the deal is not completed by December 19, 2026

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECJan 26, 2026, 7:54 AM ET
Accession number0001193125-26-021718

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.